XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jun. 01, 2021
Jan. 01, 2021
Dec. 30, 2019
Jan. 31, 2020
Sep. 30, 2021
Sep. 30, 2022
Dec. 31, 2021
Jan. 31, 2019
Loss Contingencies [Line Items]                
Options grant in period         0 980,075    
Asset Purchase Agreement [Member]                
Loss Contingencies [Line Items]                
Asset acquisition description     the Company acquired a series of small molecule analogues pursuant to an Asset Purchase Agreement (“APA”). Pursuant to the APA, the Company is required to make a payment of $50,000 upon raising of at least $2.0 million in funding, and up to $1.75 million based upon successfully meeting clinical and sales milestones          
Payments to acquire productive assets           $ 0 $ 0  
Milestone payment           $ 50,000 $ 50,000  
Employee Agreement [Member] | Chief Executive Officer [Member]                
Loss Contingencies [Line Items]                
Accrued salaries               $ 200,000
Stock issued during period, shares, employee stock purchase plans   18,939   7,575        
Proceeds from issuance or sale of equity   $ 5,000,000.0   $ 3,000,000.0        
Share issued price per share   $ 7.82            
Options grant in period   757,575            
Employee Agreement [Member] | Chief Executive Officer [Member] | Minimum [Member]                
Loss Contingencies [Line Items]                
Proceeds from issuance or sale of equity   $ 5,000,000.0            
Employee Agreement [Member] | Chief Executive Officer [Member] | Minimum [Member] | Investor [Member]                
Loss Contingencies [Line Items]                
Proceeds from issuance or sale of equity   $ 5,000,000.0            
Restated Employment Agreement [Member] | Chief Executive Officer [Member]                
Loss Contingencies [Line Items]                
Share issued price per share $ 4.00              
Options grant in period 757,575              
Professional fees $ 485,000              
Percentage of cash bouns recevied 55.00%              
Other commitments, description (i) $250 million, the CEO shall receive a cash payment of $150,000; (ii) $500 million, the CEO shall receive a cash payment of $350,000; and (iii) $1.0 billion, the CEO shall receive a cash payment of $750,000